Delivery Order SPE2DE21D0005-SPE2D626F146H
Award Date 11/13/25
Potential Completion Date 11/18/25
Potential Value $2.5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Fixed Price with Economic Price Adjustment
Place of Performance
Canton, MA 02021, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
65
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, was awarded a delivery order valued at $1,239.95 by the Defense Logistics Agency's Medical Supply Chain division on October 28, 2025, with an ultimate completion date of October 31, 2025. The award covers APLIGRAF, an advanced skin substitute product used for wound care and tissue regeneration. This delivery order was issued under a fixed-price contract with economic price adjustment terms and did not...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $2,479.90 by the Defense Logistics Agency's Medical Supply Chain division on September 23, 2025. The contract, which operates under a fixed-price arrangement with economic price adjustment provisions, is for the supply of APLIGRAF, an advanced wound care and tissue regeneration product. The delivery order is scheduled for completion by September 26, 2025, and was awarded...
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, was awarded a delivery order valued at $1,239.95 for APLIGRAF, an advanced wound care and tissue regeneration product. The contract was issued on October 14, 2025, with an ultimate completion date of October 17, 2025, and carries fixed-price pricing with economic price adjustment terms. No set-aside designation was utilized for this award. The contract is funded through the Defense Logistics Agency's...
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, was awarded a delivery order valued at $1,239.95 for APLIGRAF, an advanced wound care and tissue regeneration product. The contract, awarded on May 30, 2025, with an ultimate completion date of June 4, 2025, utilizes fixed-price pricing with economic price adjustment terms. The award was made without a set-aside designation, indicating that Organogenesis competed as a standard commercial vendor. The...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, received a delivery order for APLIGRAF from the Defense Logistics Agency (DLA) Medical Supply Chain on October 15, 2025. This fixed-price contract with economic price adjustment carries a ceiling value of $2,479.90 and is scheduled for completion by October 20, 2025. The award was made without any set-aside designation, indicating Organogenesis competed as a standard commercial vendor. APLIGRAF is an advanced...
- Organogenesis Inc. was awarded a delivery order valued at $2,479.90 by the Defense Logistics Agency's Medical Supply Chain division on September 29, 2025, for the supply of APLIGRAF, an advanced wound care and tissue regeneration product. The contract, which carries no set-aside designation, is fixed-price with economic price adjustment provisions and is scheduled for completion by October 2, 2025. Performance will take place at Organogenesis's headquarters in Canton, Massachusetts. This...
- On May 12, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $1,239.95 to Organogenesis Inc. for APLIGRAF, an advanced regenerative medicine product used in wound care and tissue regeneration. The contract is classified as fixed price with economic price adjustment and carries an ultimate completion date of May 15, 2025. This delivery order was issued without set-aside designation, reflecting Organogenesis's status as a standard commercial vendor...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $3,400 on July 17, 2025, by the Defense Logistics Agency's Medical Supply Chain division. The delivery order, which carries a fixed-price contract type with economic price adjustment provisions, is for PURAPLY AM XT EF, a 5-layer fenestrated advanced wound care product. The contract does not utilize a set-aside designation, indicating Organogenesis competed as a standard...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a $8,500 fixed-price delivery order with economic price adjustment by the Defense Logistics Agency's Medical Supply Chain division on May 30, 2025. The delivery order, with an ultimate completion date of June 4, 2025, covers PURAPLY AM XT EF, a five-layer fenestrated advanced wound care product. This award was made without a set-aside designation, indicating that Organogenesis competed as a standard...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a $3,400 fixed-price delivery order with economic price adjustment authority by the Defense Logistics Agency's Medical Supply Chain on October 1, 2025. The delivery order is for PURAPLY AM XT EF, a five-layer fenestrated advanced wound care product, with an ultimate completion date of October 6, 2025. This award was made without any set-aside designation, indicating that Organogenesis competed as a...